Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
March 13, 2019 09:00 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International...
Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
March 08, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 08, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018, and provided...
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
March 01, 2019 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31,...
Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
February 12, 2019 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the...
Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
January 28, 2019 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed...
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
December 05, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients - - Conference Call and Webcast Presentation at 8:30 a.m. ET Today - SAN DIEGO, Dec. ...
Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
November 08, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral presentations and posters addressing clinical and preclinical...
Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
November 01, 2018 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
October 25, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after...
Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
October 02, 2018 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase...